छोड़कर सामग्री पर जाएँ

AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 billion deal

  • द्वारा
  • Latest News

The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.

Top 100 Best Sellers

Read More

​ The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met. The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी
en_USEnglish hi_INहिन्दी